Frederick Banting sold the insulin patent for one dollar so no one would die for lack of access. That was 1923. A vial of the same insulin now costs $300+. Three companies control 90% of the US market. A Senate investigation documented synchronized price increases. People are documented as dying from rationing. Walmart sells it for $25.
Frederick Banting and Charles Best discovered insulin at the University of Toronto in 1921. Banting sold his patent rights to the University for $1. Best did the same. Their documented position: insulin belonged to humanity. The University licensed it to manufacturers at nominal royalties specifically to enable broad access.
The patent on insulin itself expired decades ago. The molecule is not patented. What is patented: every reformulation, every delivery device, every manufacturing process modification that the three dominant manufacturers have filed in the century since. The original gift was given. The gift was then enclosed.
Eli Lilly, Novo Nordisk, and Sanofi control approximately 90% of the US insulin market. These three manufacturers did not invent new insulin molecules. They produce analogs — slightly modified versions of existing insulin — which they patent separately. The underlying biological mechanism is the same insulin Banting discovered.
The Senate Finance Committee (2021) investigated the pricing practices of all three manufacturers. The documented finding: price increases were synchronized — all three raised prices around the same time, by similar percentages, year after year, without documented explicit coordination. The committee described this as shadow pricing — each manufacturer tracking and matching the others' increases. The legal threshold for criminal cartel prosecution (documented agreement or communication) was not reached. The documented pricing behavior is indistinguishable from cartel behavior in its effect on patients.
Alec Smith aged off his parents' insurance when he turned 26. He was a Type 1 diabetic. His insulin cost $1,300 per month without insurance. He made too much money to qualify for Medicaid. He couldn't afford the full amount. He began rationing. He was found dead in his apartment one month after aging off coverage. His mother, Nicole Smith-Holt, documented his case and became an advocate for insulin access legislation.
Alec Smith is not the only documented case. The JDRF and insulin access advocates have documented multiple deaths from insulin rationing. The documented deaths are not a failure of the system. They are a documented output of the pricing architecture.
The Walmart ReliOn proof: Walmart sells human insulin over-the-counter for $25 per vial — the same insulin molecule Banting discovered. The manufacturing cost of insulin is documented to be approximately $3–10 per vial (estimate documented in academic literature). The $300 price of analog insulin is not a manufacturing cost. It is a patent monopoly price. The $25 OTC price is the floor. The gap between $25 and $300 is the documented extraction margin.
Patent evergreening is the documented practice of filing new patents on existing drugs to extend effective market exclusivity beyond the original 20-year patent window. The Feldman study (2018, Yale Journal of Law and Technology) documented that 78% of new drug patents associated with already-approved drugs were for existing drugs — not new molecular entities.
What gets patented in a thicket strategy:
Humira (AbbVie) is the documented apex case. The drug's core patent expired in the EU in 2018. Biosimilar manufacturers entered the European market. US patients continued paying full price until January 2023 — five additional years of monopoly pricing enforced not by the original patent but by 257 additional patents filed into a thicket so dense that biosimilar companies chose to negotiate delayed entry rather than litigate their way through every patent.
A pay-for-delay agreement — also called a reverse payment settlement — is a contract in which a brand pharmaceutical manufacturer pays a generic manufacturer to delay entering the market. The payment flows in the opposite direction from what logic would suggest: the company being challenged pays the challenger to stand down.
The Supreme Court addressed pay-for-delay in FTC v. Actavis (2013). The Court ruled 5-3 that reverse payment settlements can be anticompetitive and the FTC can challenge them under antitrust law. The ruling did NOT ban them. It said each case could be challenged individually. The practice continued — companies restructured agreements to use non-cash forms (authorized generics, royalty-free licenses) achieving the same market exclusion with less legal exposure.
Documented cases: Cephalon/Provigil paid four generic manufacturers over $200 million to stay off the market. AndroGel (Abbott/Solvay). K-Dur (Schering-Plough). AbbVie structured biosimilar settlement agreements with multiple manufacturers to delay US entry of Humira biosimilars until January 2023 — five years after European biosimilar competition began.
The Walmart proof collapses the entire "manufacturing cost" argument in one data point. Walmart sells human insulin — the original Banting molecule — over-the-counter for $25. Eli Lilly sells Humalog — an analog — for $300+. The difference between $25 and $300 is not production cost, regulatory compliance, or R&D recovery. It is the documented price of a patent monopoly.
A man sold a life-saving discovery for $1 so no one would die for lack of it. A century later, three companies control 90% of the market, raise prices in documented synchronized lockstep, file hundreds of patents on minor modifications to prevent generic competition, and pay generic manufacturers not to compete. People die from rationing a molecule that costs $25 at Walmart. Every legal mechanism that could have stopped this — antitrust enforcement, patent law reform, pricing negotiation — was either never applied or explicitly prohibited by statute. The architecture is not broken. It is documented as working exactly as the lobbying investment designed it to work.
In the Frieza Matrix, the insulin architecture is the clearest documented example of manufactured scarcity applied to the sustenance of life. Banting understood that insulin is not a commodity — it is the mechanism by which a body converts food into energy. It is, in the most literal biological sense, the means by which a human maintains sovereignty over their own continued existence.
The documented inversion: Banting gave it away precisely to prevent it from becoming a tool of control. The architecture that followed is the documented reversal of that gift. A publicly discovered molecule, sold for $1 to the world, was systematically enclosed through patent after patent until the $1 gift became a $300 toll gate on survival. The person with Type 1 diabetes who cannot afford insulin does not have a medical problem. They have a sovereignty problem. Their continued existence is being metered by a pricing architecture.
The loosh dimension: the documented fear response in a person rationing insulin — the calculation of days, the anxiety of supply, the impossible arithmetic of survival vs. rent vs. groceries — is one of the highest-frequency documented fear states a human can sustain chronically. The architecture that produces it does not require malice. It requires only that the incentive structure reward maintenance of the toll gate. The outcome is the same.
In the inner knowledge framework, a gift given unconditionally to humanity — healing knowledge placed freely in the commons — is precisely what the archonic architecture is documented as systematically retrieving and placing behind barriers. The mystery school → institutional religion pattern. The NIH → Bayh-Dole pattern. The Banting $1 → $300 cartel pattern. The structure is identical across contexts: access to what sustains and heals is removed from the sovereign individual and placed behind a toll gate operated by an intermediary. Recognition of the mechanism is the first step toward refusing it.